Synergistic Effects of TW-37 and ABT-263 on Renal Cell Carcinoma Cells

References

• Gerlinger M, Horswell S, Larkin J. Genomic architecture and evolution of clear cell renal cell carcinomas defined by multiregion sequencing. Nat Genet. 2014;46(3):225–233. doi:10.1038/ng.289124487277
   PubMed Web of Science ®Google Scholar
• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin. 2018;68(1):7–30. doi:10.3322/caac.2144229313949
   PubMed Web of Science ®Google Scholar
• Jabaji RB. Trend of surgical treatment of localized renal cell carcinoma. Perm J. 2019;23:18–108.
   Google Scholar
• Sanchez-Gastaldo A, Kempf E, González Del Alba A, et al. Systemic treatment of renal cell cancer: a comprehensive review. Cancer Treat Rev. 2017;60:77–89. doi:10.1016/j.ctrv.2017.08.01028898679
   PubMed Web of Science ®Google Scholar
• Posadas EM, Limvorasak S, Figlin RA. Targeted therapies for renal cell carcinoma. Nat Rev Nephrol. 2017;13(8):496–511. doi:10.1038/nrneph.2017.8228691713
   PubMed Web of Science ®Google Scholar
• Barata PC, Rini BI. Treatment of renal cell carcinoma: current status and future directions. CA Cancer J Clin. 2017;67(6):507–524. doi:10.3322/caac.2141128961310
   PubMed Web of Science ®Google Scholar
• Lei S, Ding Y, Fu Y, et al. The preclinical analysis of TW-37 as a potential anti-colorectal cancer cell agent. PLoS One. 2017;12(10):e0184501. doi:10.1371/journal.pone.018450129065135
   PubMed Web of Science ®Google Scholar
• Mohammad RM, Goustin AS, Aboukameel A, et al. Preclinical studies of TW-37, a new nonpeptidic small-molecule inhibitor of Bcl-2, in diffuse large cell lymphoma xenograft model reveal drug action on both Bcl-2 and Mcl-1. Clin Cancer Res. 2007;13(7):2226–2235. doi:10.1158/1078-0432.CCR-06-157417404107
   PubMed Web of Science ®Google Scholar
• Wang G, Nikolovska-Coleska Z, Yang C-Y, et al. Structure-based design of potent small-molecule inhibitors of anti-apoptotic Bcl-2 proteins. J Med Chem. 2006;49(21):6139–6142. doi:10.1021/jm060460o17034116
   PubMed Web of Science ®Google Scholar
• Ahn CH, Lee WW, Jung YC, et al. Antitumor effect of TW-37, a BH3 mimetic in human oral cancer. Lab Anim Res. 2019;35(1):27. doi:10.1186/s42826-019-0028-732257914
   PubMed Web of Science ®Google Scholar
• Klenke S, Akdeli N, Stelmach P, et al. The small molecule Bcl-2/Mcl-1 inhibitor TW-37 shows single-agent cytotoxicity in neuroblastoma cell lines. BMC Cancer. 2019;19(1):243. doi:10.1186/s12885-019-5439-130885150
   PubMed Web of Science ®Google Scholar
• Chen X, Mao G, Chen H, et al. TW37 enhances the pro-apoptosis and anti-migration ability of gefitinib in non-small cell lung cancer. Cell Mol Biol (Noisy-Le-Grand). 2018;64(4):6–10. doi:10.14715/cmb/2018.64.4.2
   PubMed Web of Science ®Google Scholar
• Wang Z, Song W, Aboukameel A, et al. TW-37, a small-molecule inhibitor of Bcl-2, inhibits cell growth and invasion in pancreatic cancer. Int J Cancer. 2008;123(4):958–966. doi:10.1002/ijc.2361018528859
   PubMed Web of Science ®Google Scholar
• Lu Y, Huang H, Yang H, et al. Small molecule inhibitor TW-37 is tolerable and synergistic with chemotherapy in nasopharyngeal carcinoma. Cell Cycle. 2017;16(14):1376–1383. doi:10.1080/15384101.2017.132906628696828
   PubMed Web of Science ®Google Scholar
• Gobe G, Rubin M, Williams G, et al. Apoptosis and expression of Bcl-2, Bcl-X L, and bax in renal cell carcinomas. Cancer Invest. 2002;20(3):324–332. doi:10.1081/CNV-12000117712025227
   PubMed Web of Science ®Google Scholar
• Tse C, Shoemaker AR, Adickes J, et al. ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor. Cancer Res. 2008;68(9):3421–3428. doi:10.1158/0008-5472.CAN-07-583618451170
   PubMed Web of Science ®Google Scholar
• Oltersdorf T, Elmore SW, Shoemaker AR, et al. An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature. 2005;435(7042):677–681. doi:10.1038/nature0357915902208
   PubMed Web of Science ®Google Scholar
• Kipps TJ, Eradat H, Grosicki S, et al. A Phase 2 study of the BH3 mimetic BCL2 inhibitor navitoclax (ABT-263) with or without rituximab, in previously untreated B-cell chronic lymphocytic leukemia. Leuk Lymphoma. 2015;56(10):2826–2833. doi:10.3109/10428194.2015.103063825797560
   PubMed Web of Science ®Google Scholar
• Yu R, Yao J, Ren Y. A novel circRNA, circNUP98, a potential biomarker, acted as an oncogene via the miR-567/PRDX3 axis in renal cell carcinoma. J Cell Mol Med. 2020;24(17):10177–10188. doi:10.1111/jcmm.1562932729669
   PubMed Web of Science ®Google Scholar
• Yu R, Yu B-X, Chen J-F, et al. Anti-tumor effects of atractylenolide I on bladder cancer cells. J Exp Clin Cancer Res. 2016;35(1):40. doi:10.1186/s13046-016-0312-426931119
   PubMed Web of Science ®Google Scholar
• Chou T-C. Preclinical versus clinical drug combination studies. Leuk Lymphoma. 2008;49(11):2059–2080. doi:10.1080/1042819080235359119021049
   PubMed Web of Science ®Google Scholar
• Itoi T, Yamana K, Bilim V, et al. Impact of frequent Bcl-2 expression on better prognosis in renal cell carcinoma patients. Br J Cancer. 2004;90(1):200–205. doi:10.1038/sj.bjc.660145414710230
   PubMed Web of Science ®Google Scholar
• Zhu S, Cohen MB, Bjorge JD, et al. PI3K inhibition potentiates Bcl-2-dependent apoptosis in renal carcinoma cells. J Cell Mol Med. 2013;17(3):377–385. doi:10.1111/jcmm.1201923387989
   PubMed Web of Science ®Google Scholar
• Yin P, Jia J, Li J, et al. ABT-737, a Bcl-2 selective inhibitor, and chloroquine synergistically kill renal cancer cells. Oncol Res. 2016;24(1):65–72. doi:10.3727/096504016X1458736698383827178823
   PubMed Web of Science ®Google Scholar
• Dai H, Meng XW, Kaufmann SH. Mitochondrial apoptosis and BH3 mimetics. F1000Res. 2016;5:2804. doi:10.12688/f1000research.9629.127990281
   PubMedGoogle Scholar
• Brumatti G, Ekert PG. Seeking a MCL-1 inhibitor. Cell Death Differ. 2013;20(11):1440–1441. doi:10.1038/cdd.2013.11424096932
   PubMed Web of Science ®Google Scholar
• Piva F, Giulietti M, Santoni M, et al. Epithelial to mesenchymal transition in renal cell carcinoma: implications for cancer therapy. Mol Diagn Ther. 2016;20(2):111–117. doi:10.1007/s40291-016-0192-526940073
   PubMed Web of Science ®Google Scholar
• Wang Z, Azmi AS, Ahmad A, et al. TW-37, a small-molecule inhibitor of Bcl-2, inhibits cell growth and induces apoptosis in pancreatic cancer: involvement of notch-1 signaling pathway. Cancer Res. 2009;69(7):2757–2765. doi:10.1158/0008-5472.CAN-08-306019318573
   PubMed Web of Science ®Google Scholar
• Sale MJ, Cook SJ. The BH3 mimetic ABT-263 synergizes with the MEK1/2 inhibitor selumetinib/AZD6244 to promote BIM-dependent tumour cell death and inhibit acquired resistance. Biochem J. 2013;450(2):285–294. doi:10.1042/BJ2012121223234544
   PubMed Web of Science ®Google Scholar
• Zhan Y, Wang Y, Qi M, et al. BH3 mimetic ABT-263 enhances the anticancer effects of apigenin in tumor cells with activating EGFR mutation. Cell Biosci. 2019;9(1):60. doi:10.1186/s13578-019-0322-y31367332
   PubMed Web of Science ®Google Scholar
• Lian BSX, Yek AEH, Shuvas H, et al. Synergistic anti-proliferative effects of combination of ABT-263 and MCL-1 selective inhibitor A-1210477 on cervical cancer cell lines. BMC Res Notes. 2018;11(1):197. doi:10.1186/s13104-018-3302-029580266
   PubMedGoogle Scholar
• Wang B, Ni Z, Dai X, et al. The Bcl-2/xL inhibitor ABT-263 increases the stability of Mcl-1 mRNA and protein in hepatocellular carcinoma cells. Mol Cancer. 2014;13(1):98. doi:10.1186/1476-4598-13-9824779770
   PubMed Web of Science ®Google Scholar
• Verhaegen M, Bauer JA, Martín de la Vega C, et al. A novel BH3 mimetic reveals a mitogen-activated protein kinase-dependent mechanism of melanoma cell death controlled by p53 and reactive oxygen species. Cancer Res. 2006;66(23):11348–11359. doi:10.1158/0008-5472.CAN-06-174817145881
   PubMed Web of Science ®Google Scholar
• Yang IH, Jung J-Y, Kim S-H, et al. ABT-263 exhibits apoptosis-inducing potential in oral cancer cells by targeting C/EBP-homologous protein. Cell Oncol. 2019;42(3):357–368. doi:10.1007/s13402-019-00431-5
   Web of Science ®Google Scholar
• Zoeller JJ, Vagodny A, Taneja K, et al. Neutralization of BCL-2/X L enhances the cytotoxicity of T-DM1 in vivo. Mol Cancer Ther. 2019;18(6):1115–1126. doi:10.1158/1535-7163.MCT-18-074330962322
   PubMed Web of Science ®Google Scholar